Opdivo Plus Experimental Drug Combo Fails to Improve Survival, Response Rates in Patients With Advanced Melanoma

Source: Cure 20, March 2022

The use of bempegaldesleukin and Opdivo failed to meet its goal of significantly improving progression-free survival and responses to treatment, compared with Opdivo alone in patients with previously untreated unresectable or metastatic melanoma, according to data from an initial analysis of the phase 3 PIVOT IO-001 study.

Patients with previously untreated unresectable or metastatic melanoma, a form of skin cancer, did not derive a survival benefit after receiving first-line treatment with Opdivo (nivolumab) in combination with the novel therapy bempegaldesleukin when compared with Opdivo alone, according to a news release issued by Bristol Myers Squibb (BMS), the manufacturer of Opdivo.

The pharmaceutical company recently provided an update on the first analysis of findings from the phase 3 PIVOT IO-001 study, which was assessing the safety and efficacy of the doublet treatment versus Opdivo alone as a potential first-line treatment option for this patient population.

READ THE ORIGINAL FULL ARTICLE